Geptanolimab

Names

[ Name ]:
Geptanolimab

Biological Activity

[Description]:

Geptanolimab (CBT-501) is a humanized IgG4k monoclonal antibody against programmed death-1 (PD-1). Siplizumab inhibits the binding of PD-L1/L2 to PD-1 through a competitive action. Siplizumab can be used in research of cancer[1].

[Related Catalog]:

Research Areas >> Cancer

Signaling Pathways >> Immunology/Inflammation >> PD-1/PD-L1

[In Vitro]

Geptanolimab (CBT-501) 与人 (KD=505 pM) 和猕猴 (KD=7.2 nM) 的 PD-1 具有高度特异性结合[ 1]。 Geptanolimab 增强混合淋巴细胞反应 (MLR) 中的人 T 细胞活化，增加 IL-2 和 INF-γ 的释放[1]。

[In Vivo]

Geptanolimab (CBT-501; ip; 每两周一次, 持续6周; MC38同系肿瘤模型小鼠) 具有抗肿瘤活性，抑瘤率达到 83%[1]。

[References]

[1]. Qing Z, et, al. Activity of CBT-501, a novel humanized anti-PD-1 antibody, in a humanized genetically engineered mouse model of colon carcinoma. Journal of Clinical Oncology. 2017;35 (7_suppl):108-108.

Chemical & Physical Properties

No Any Chemical & Physical Properties

Related Compounds

The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.